Afatinib treatment in advanced non-small cell lung cancer

References

• BaggstromMQStinchcombeTEFriedDBPooleCHensingTASocinskiMAThird-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysisJ Thorac Oncol20072984585317805063
   PubMed Web of Science ®Google Scholar
• RosellRGatzemeierUBetticherDCPhase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trialAnn Oncol200213101539154912377641
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
   PubMed Web of Science ®Google Scholar
• ZatloukalPPetruzelkaLZemanovaMGemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trialLung Cancer200341332133112928123
   PubMed Web of Science ®Google Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol200826213543355118506025
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar
• CiuleanuTBrodowiczTZielinskiCMaintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyLancet200937496991432144019767093
   PubMed Web of Science ®Google Scholar
• CataldoVDGibbonsDLPerez-SolerRQuintas-CardamaATreatment of non-small-cell lung cancer with erlotinib or gefitinibN Engl J Med36410947955
   Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• KobayashiKInoueAMaemondoMFirst-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group [abstract]J Clin Oncol20092715S8016
   Google Scholar
• LeeJSParkKKimSWA randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [abstract]Proceedings of the 13th World Conference on Lung CancerJuly 31–August 4, 2009San Francisco, CA Abstract PRS.4
   Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• ZhouCWuYChenGEfficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations [abstract]Ann Oncol201021Suppl 8LBA13
   Google Scholar
• ShepherdFADanceyJRamlauRProspective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyJ Clin Oncol200018102095210310811675
   PubMed Web of Science ®Google Scholar
• HannaNShepherdFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339
   PubMed Web of Science ®Google Scholar
• KimESHirshVMokTGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet200837296521809181819027483
   PubMed Web of Science ®Google Scholar
• JannePAEngelmanJAJohnsonBEEpidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biologyJ Clin Oncol200523143227323415886310
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAEpidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directionsJ Clin Oncol200523112556256815767641
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med20093611095896719692684
   PubMed Web of Science ®Google Scholar
• ForbesSClementsJDawsonECosmic 2005Br J Cancer200694231832216421597
   PubMed Web of Science ®Google Scholar
• MassarelliEVarella-GarciaMTangXKRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerClin Cancer Res200713102890289617504988
   PubMed Web of Science ®Google Scholar
• ZhuCQda Cunha SantosGDingKRole of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21J Clin Oncol200826264268427518626007
   PubMed Web of Science ®Google Scholar
• GiacconeGWangYStrategies for overcoming resistance to EGFR family tyrosine kinase inhibitorsCancer Treat Rev201137645646421367530
   PubMed Web of Science ®Google Scholar
• Paz-AresLSoulieresDMelezinekIClinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysisJ Cell Mol Med2010141–2516920015198
   PubMed Web of Science ®Google Scholar
• MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung-cancer cellsN Engl J Med2008359436637718596266
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med200523e7315737014
   PubMed Web of Science ®Google Scholar
• BeanJBrennanCShihJYMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProc Natl Acad Sci U S A200710452209322093718093943
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience200731658271039104317463250
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov.
   Google Scholar
• SequistLVBesseBLynchTJNeratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerJ Clin Oncol201028183076308320479403
   PubMed Web of Science ®Google Scholar
• JannePAvon PawelJCohenRBMulticenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancerJ Clin Oncol200725253936394417761977
   PubMed Web of Science ®Google Scholar
• JannePReckampKKoczywasMEfficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial [abstract]J Clin Oncol20092715S8063
   Google Scholar
• EskensFAMomCHPlantingASA phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursBr J Cancer2008981808518026190
   PubMed Web of Science ®Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene200827344702471118408761
   PubMed Web of Science ®Google Scholar
• SolcaFBaumAGuthBBIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor for cancer therapy [abstract]Proceedings, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsPhiladelphia, PANovember 14–18; 2005118 Abstract A244
   Google Scholar
• StopferPNarjesHGaschler-MarkefskiBGansserDShahidiMPharmacokinetics (PK) of [14C]-BIBW 2992 after administration of a single dose of 15 mg [14C]-BIBW 2992 oral solution in healthy male volunteers [abstract]J Clin Oncol200826Suppl14607
   Web of Science ®Google Scholar
• AgusDBTerlizziEStopferPAmelsbergAGordonMSA phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours [abstract]J Clin Oncol20062418S2074
   Google Scholar
• YapTAVidalLAdamJPhase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsJ Clin Oncol201028253965397220679611
   PubMed Web of Science ®Google Scholar
• LewisNMarshallJAmelsbergAA phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumours [abstract]J Clin Oncol20062418S3091
   Google Scholar
• JanjigianYGroenHHornLActivity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib [abstract]J Clin Oncol20112915S7525
   Web of Science ®Google Scholar
• JackmanDPaoWRielyGJClinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerJ Clin Oncol200928235736019949011
   PubMed Web of Science ®Google Scholar
• AngJMikropoulosCStavridiFA phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel [abstract]J Clin Oncol20092715Se14541
   Google Scholar
• AwadaADumezHWolterPA phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors [abstract]J Clin Oncol20092715Se3556
   Google Scholar
• BahledaRSoriaJBergeYPhase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors [abstract]J Clin Oncol20112915S2585
   Web of Science ®Google Scholar
• VermorkenJMachielsJRotteySThurmHPellingKLahogueAPhase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5-FU (PF), in patients with advanced solid tumors [abstract]J Clin Oncol201028Supple13521
   Google Scholar
• MillerVAHirshVCadranelJPhase IIb/III double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1) [abstract]. European Society of Medical Oncology (ESMO) Congress, Milan, Italy, October 2010Ann Oncol201021Suppl 8viii1
   Google Scholar
• MillerVASubgroup analysis of LUX-Lung 1; A randomised phase III trial of Afatinib (BIBW 2992) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinibOral presentation at Chicago Multidisciplinary Symposium in Thoracic OncologyChicago, ILDecember, 2010
   Google Scholar
• YangGShihJSuWA phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-LUNG 2) [abstract]J Clin Oncol20102815s7521
   Web of Science ®Google Scholar
• ShihJYuCSuWActivity of BIBW 2992, an irreversible EGFR/HER1 and HER2 TKI, in lung adenocarcinoma patients harbouring less common EGFR mutations [abstract]Annals Oncol201021Suppl 8viii122viii161415P
   Google Scholar
• YamamotoNKatakamiNAtagiSA phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G) [abstract]J Clin Oncol20112915S7524
   Web of Science ®Google Scholar
• KristeleitHPuglisiMMiddletonGPhase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy [abstract]J Clin Oncol20112915S2613
   Web of Science ®Google Scholar